Gordon Crofoot

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E. Sax, David A. Wohl, Michael T. Yin et al. · The Lancet · 2015 · 598 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Clinical targeting of HIV capsid protein with a long-acting small molecule

John O. Link, Martin S. Rhee, Winston C. Tse et al. · Nature · 2020 · 421 citations · Full text

Pharmacy, Molecular Biology, Pharmaceutics +12

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

Colleen F. Kelley, Maribel Acevedo-Quiñones, Allison L. Agwu et al. · New England Journal of Medicine · 2024 · 229 citations

Public Health, Pharmacology, Pharmacotherapy +17

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment

Anton Pozniak, José Ramón Arribas, Joseph Gathe et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2015 · 184 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17